<DOC>
	<DOCNO>NCT02903004</DOCNO>
	<brief_summary>This open-label , prospective , multicenter , randomize Phase III , clinical trial evaluate efficacy safety trabectedin BRCA1 BRCA2 mutation carrier BRCAness phenotype advance ovarian cancer patient comparison physician ' choice chemotherapy . Arm A : Trabectedin 1.3 mg/mq d1 q 21 3 hour ( central line ) Arm B : Pegylated Liposomal Doxorubicin 40 mg/mq q 28 Topotecan 4 mg/mq dd 1,8,15 q 28 Gemcitabine 1000 mg/mq dd 1 , 8 , 15 q 28 Weekly Paclitaxel 80 mg/mq gg 1 , 8 , 15 q 28 Carboplatin AUC 5-6 q 21 28 Patients randomly assign 1:1 ratio treatment arm . During randomization process , patient stratify - Platinum sensitivity - Measurable disease - Number previous chemotherapy line &gt; v &lt; 3 - BRCA mutational status</brief_summary>
	<brief_title>Trial Trabectedin ( ET-743 ) v Clinician 's Choice Chemotherapy Recurrent Ovarian , Primary Peritoneal Fallopian Tube Cancers BRCA Mutated BRCAness Phenotype Patients _MITO-23</brief_title>
	<detailed_description>Subjects randomize 1:1 ratio receive one follow treatment : Arm A : Trabectedin 1.3 mg/m2 d1 q 21 3 hour ( central line ) Arm B : Pegylated Liposomal Doxorubicin 40 mg/mq q 28 Topotecan 4 mg/ m2 dd 1,8,15 q 28 Gemcitabine 1000 mg/mq dd 1 , 8 , 15 q 28 Weekly Paclitaxel 80 mg/ m2 dd 1 , 8 , 15 q 28 Carboplatin AUC 5-6 q 21 28 Randomization stratify base platinum-free interval ( PFI ) ( PFI ≥ 0 ≤ 6 month vs. PFI &gt; 6 month ) , presence / absence measurable disease/number previous chemotherapy line , germline BRCA mutational status v BRCAness phenotype . Platinum-free interval ( PFI ) define time last dose platinum contain regimen first date progression . Subjects continue receive chemotherapy treatment disease progression ( clinical progression mean global deterioration health status attributable disease require change therapy without objective evidence progression consider progression disease ) , intolerability , patient refusal , investigator decision death cause . Subjects evaluate every 12 week ± 1 week Response Evaluation Criteria Solid Tumors ( RECIST 1.1 ) objective radiographic response radiographic disease progression .</detailed_description>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Trabectedin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>1 . Female age 18 year old 2 . Histologically cytologically document invasive epithelial ovarian cancer , primary peritoneal carcinoma , fallopian tube cancer 3 . Platinum resistant sensitive patient either : 1 . BRCA mutate patient 2 . BRCAness phenotype patient : patient receive responded ( subsequent PFI &gt; 6 month ) least 2 previous platinum base chemotherapy line 3 . Platinum sensitive patient able receive willing receive platinum treatment 4 . Measurable evaluable disease per RECIST 1.1 ( Subjects isolate rise CA125 without radiologically visible disease exclude ) 5 . ECOG performance status 0 1 6 . No limit number previous chemotherapy line , previous treatment parp inhibitor allow 7 . Left Ventricular Ejection Fraction ( LVEF ) ≥ institutional low limit normal 8 . Life expectancy least 3 month 9 . Adequate organ function : 1 . Hematopoietic : Absolute neutrophil count ≥ 1,500/mm3 ; Platelet count ≥ 100,000/mm3 ; Hemoglobin ≥ 9 g/dl 2 . Hepatic : AST ALT ≤ 1.5 time upper limit normal ( ULN ) * ; Alkaline Phosphatase ≤ 2.5 time ULN* ; Bilirubin ≤ 1.5 time ULN . NOTE : * ≤ 3 time ULN liver metastases present 3 . Renal : Creatinine Clearance ≥ 45 ml/min Serum Creatinine ≤1.5 x ULN 4 . Serum Albumin &gt; 2.5 g/dl 10 . No invasive malignancy within past 3 year except nonmelanoma skin cancer situ cervical cancer ( patient previous cancer may enrol providing recurrence report last 3 year ) 11 . Written Informed Consent 12 . Adequately recover acute toxicity prior treatment 13 . For agent standard arm , also refer local prescribe information regard warning , precaution , contraindication 1 . Prior exposure trabectedin 2 . Known hypersensitivity component trabectedin i.v . formulation dexamethasone 3 . Subjects borderline ovarian cancer , ie . Subject low malignant potential tumor exclude 4 . Less 2 report response platinum ( i.e . subsequent recurrence least 6 month first second platinum base treatment ) , unless BRCA mutation document . 5 . Less 4 week last dose therapy investigational agent , chemotherapy 6 . History another neoplastic disease ( except basal cell carcinoma cervical carcinoma situ adequately treat ) unless remission 3 year longer 7 . Known clinically relevant CNS metastasis , unless treat asymptomatic 8 . Other serious illness , : 1 . Congestive heart failure angina pectoris ; myocardial infarction within 1 year enrolment ; uncontrolled arterial hypertension arrhythmia . 2 . Psychiatric disorder prevents compliance protocol . 3 . Active viral hepatitis ; chronic liver disease . 4 . Active infection . 5 . Any unstable medical condition .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>